Table 1. Efficacy of daclatasvir and sofosbuvir in hepatitis C.
| Study | Viral genotype | Treatment regimen | Sustained virological response‡ | |
|---|---|---|---|---|
| Treatment-naïve patients | Treatment-experienced patients | |||
| Sulkowski2 | 1 | daclatasvir + sofosbuvir§ | 100% (70/70) | 100% (21/21) |
| daclatasvir + sofosbuvir + ribavirin§ | 98% (55/56) | 100% (20/20) | ||
| 2 or 3 | daclatasvir + sofosbuvir§ | 93% (28/30) | - | |
| daclatasvir + sofosbuvir + ribavirin§ | 93% (13/14) | - | ||
| Nelson3 | 3 | daclatasvir + sofosbuvir# | Overall 90% (91/101) |
Overall 86% (44/51) |
| Patients with cirrhosis 58% (11/19) |
Patients with cirrhosis 69% (9/13) |
|||
‡ Defined as proportion of patients with viral RNA less than the lower limit of quantification in serum, measured 12 weeks after the end of treatment.
§ Treatment given for 12 or 24 weeks in treatment-naïve patients and for 24 weeks in treatment-experienced patients.
# Treatment given for 12 weeks.